Format

Send to

Choose Destination
J Clin Invest. 2018 Dec 3;128(12):5351-5367. doi: 10.1172/JCI121876. Epub 2018 Oct 29.

Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets.

Author information

1
Cell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
2
Department of Cell Death and Proliferation, Institut d'Investigacions Biomèdiques de Barcelona-Consejo Superior de Investigaciones Científicas- Institut d'Investigacions Biomèdiques August Pi i Sunyer- (IIBB-CSIC-IDIBAPS), Barcelona, Spain.
3
ProteoRed - Instituto de Salud Carlos III (ISCIII) and Proteomics Unit, CNIO, Madrid, Spain.
4
Cytometry Unit, CNIO, Madrid, Spain.

Abstract

MASTL, a Ser/Thr kinase that inhibits PP2A-B55 complexes during mitosis, is mutated in autosomal dominant thrombocytopenia. However, the connections between the cell-cycle machinery and this human disease remain unexplored. We report here that, whereas Mastl ablation in megakaryocytes prevented proper maturation of these cells, mice carrying the thrombocytopenia-associated mutation developed thrombocytopenia as a consequence of aberrant activation and survival of platelets. Activation of mutant platelets was characterized by hyperstabilized pseudopods mimicking the effect of PP2A inhibition and actin polymerization defects. These aberrations were accompanied by abnormal hyperphosphorylation of multiple components of the actin cytoskeleton and were rescued both in vitro and in vivo by inhibiting upstream kinases such as PKA, PKC, or AMPK. These data reveal an unexpected role of Mastl in actin cytoskeletal dynamics in postmitotic cells and suggest that the thrombocytopenia-associated mutation in MASTL is a pathogenic dominant mutation that mimics decreased PP2A activity resulting in altered phosphorylation of cytoskeletal regulatory pathways.

KEYWORDS:

Cell Biology; Cell cycle; Hematology; Phosphoprotein phosphatases; Thrombosis

PMID:
30252678
PMCID:
PMC6264735
[Available on 2019-03-03]
DOI:
10.1172/JCI121876
Free full text

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation
Loading ...
Support Center